Kornimate/medical-research-clean huggingface dataset:
non-exudative age-related macular degeneration

Conditions: Non-exudative Age-related Macular Degeneration

Summary: age-related macular degeneration (amd) is the most prevalent cause of vision loss in developed countries and is often discussed in terms of the "dry" and the "wet" forms. the "wet" form of amd is the more advanced form of the disease and is responsible for 80% of the legal blindness in amd. treatment options include a promising class of biologics called anti-vascular endothelial growth factors, as well as photodynamic therapy and laser surgery. these therapies can slow further vision loss, but cannot achieve recovery of lost vision. the "wet" form of amd is always preceded by the "dry" form. therefore, it is reasonable to expect that the early detection and treatment of the "dry" form may help reduce vision loss or progression to the more damaging "wet" form. unfortunately, symptoms appear only in advanced stages of the "dry" form. as light sensitive cells in the macula breakdown in a process called geographic atrophy, the patient may notice blurred central vision. oct is an imaging technology that can perform non-contact cross-sectional imaging of retinal and choroidal tissue structure in real time. it is analogous to ultrasound b-mode imaging, except that oct measures the intensity of reflected light rather than acoustical waves. this study aims is to use oct technology to compare how the retinal anatomy and blood flow differ within three severity groupings of non-exudative age-related macular degeneration (neamd).


Eligibility criteria:
inclusion criteria: * presence of mild, moderate or severe neamd. * media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs. * vision better than 20/200 exclusion criteria: * inability to give informed consent. * inability to maintain stable fixation for oct imaging. * a condition that, in the opinion of the investigator, would preclude participation in the study (e.g. unstable medical status including blood pressure, cardiovascular disease, and glycemic control). * a concurrent ocular pathology that may contribute to vision loss (e.g., cnv, glaucoma, visually significant cataract, optic neuropathy, diabetic retinopathy, history of retinal surgery) or interfere with acquisition of high-quality images * blood pressure \> 180/110 (systolic above 180 or diastolic above 110). if blood pressure is brought below 180/110 by anti-hypertensive treatment, subject can become eligible. * an ocular condition is present that, in the opinion of the investigator, might affect or alter visual acuity during the course of the study (e.g., vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.). * substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal). * unable to ambulate and take tram from clinic to where oct is located

Keywords: dry amd age-related macular degeneration optical coherenece tomography imaging blood flow
omitting drains after repair of peptic ulcer perforations

Conditions: Peptic Ulcer Perforations

Summary: . this study aimed to evaluate eras application outcomes via omitting the intraabdominal drains compared to regular using of the drains in patients undergoing perforated duodenal ulcer repairs in emergency abdominal surgeries.

patients will be randomly assigned into two groups. in group a : the investigators will put intraabdominal drains, and in group ,thd investigators will not put any intraabdominal drains. our primary outcomes will be hospital stayl engthand pain score;data analysis packages will be spss version 21 qualitative data will be presented by number and percentage, quantitative data by mean, standard deviation, median and interquartile range.

Eligibility criteria:
inclusion criteria: - patients older than 18 years with perforated peptic ulcer who underwent exploratory laparotomy or laparoscopy and repair with omental pedicle techniques will included in the study. exclusion criteria: * preoperative shock on admission. * delayed presentation more than 24 hours. * known malignant gastric ulcers confirmed by histopathology. * the presence of neuropsychiatric disease, pregnant and lactating women. * predisposing factors for impaired wound healing (e.g., currently using immunosuppressive agents, or chronic use of steroids), the presence of hiv/aids. * intraoperative findings consistent with malignant ulcers. • american society of anesthesiologists grade iii/iv, or had an alternative perioperative diagnosis. • ulcer size more than 2 cm in diameter.
patient reported outcomes in adults with severe eosinophilic asthma on benralizumab.

Conditions: Severe Eosinophilic Asthma

Summary: this study will generate patient reported outcomes (pros) associated with the use of benralizumab as treatment for severe eosinophilic asthma.

benralizumab was launched in 2018 following regulatory approval in canada and is now widely available for canadian patients with severe eosinophilic asthma. this study is an observational cohort study of patient reported outcomes (pros) within real-world settings for participants who are prescribed benralizumab for treatment of uncontrolled severe eosinophilic asthma. patients will be recruited in select clinics across canada. survey data for each participant in the study will be obtained at the following time-points: * baseline (week 0) * short-term follow up: 1-, 2-, 4-, and 8-weeks after baseline * long-term follow-up: 24- and 56-weeks after baseline

Eligibility criteria:
the following individuals may be eligible to participate: * are enrolled in the benralizumab psp; * are 18 years of age or older; * can understand the requirements of the study and provide informed consent to participate in this study; * agree to abide by the study protocol and the exclusion criteria and can complete all aspects of the study, including all visits. * are benralizumab naïve and have not previously received benralizumab prior to the start of this study and * suffer from uncontrolled severe eosinophilic asthma meeting at least one of the following: 1. has blood eosinophil count ≥ 300 cells/μl and experienced two or more clinically-significant exacerbations in the past 12 months; or 2. has blood eosinophil count ≥ 150 cells/μl and are treated chronically with oral corticosteroids (ocs); or 3. sputum eosinophil levels of 3% and higher or 4. have been previously treated with a biologic for severe asthma and previously met the above eosinophil counts (detailed in #1,2, or 3 above) prior to initiation of the previous biologic. and * acq-6 score ≥ 1.5 exclusion criteria: any of the following conditions are cause for exclusion from the study: * patients currently enrolled in an interventional clinical study in parallel will be excluded from the study, except for patients who are in parallel documented in a national asthma registry; * patients who have previously received benralizumab prior to the start of the study * patients currently participating (i.e. have not completed) in any other clinical trial including those with biologic treatment; * patients with other documented lung disease other than asthma and not within reimbursed label.
clonal mast cell disorders in exercise-induced anaphylaxis

Conditions: Anaphylaxis

Summary: anaphylaxis is a serious allergic reaction that develops rapidly and can cause death. some patients experience anaphylaxis is association with exercise, a disorder called exercise-induced anaphylaxis. a subset of patients with unexplained anaphylaxis, especially those with hypotension during the anaphylactic episodes, have been shown to have abnormal, clonal populations of a certain cell type, mast cells, in the bone marrow. this has been described in at least one patient with exercise-induced anaphylaxis. the investigators would like review the findings in a group of patients with exercise-induced anaphylaxis who have undergone evaluation for the presence of abnormal, clonal mast cells.


Eligibility criteria:
inclusion criteria: * anaphylaxis in association with exercise on at least two occasions * during anaphylactic reaction, the subject must have experienced one or more of the following: flushing, hypotension, lack of urticaria exclusion criteria: * pregnancy

Keywords: clonal mast cell disorder exercise-induced anaphylaxis hypotension
evaluate the safety, tolerability, and efficacy of icp-490 in patients with relapsed or refractory non-hodgkin lymphoma

Conditions: Relapsed or Refractory Non-Hodgkin Lymphoma

Summary: this is a multi-center, non-randomized and open-label phase i/iia clinical study to evaluate the safety, tolerability, and efficacy of icp-490 in patients with relapsed or refractory non-hodgkin lymphoma.


Eligibility criteria:
inclusion criteria 1. aged ≥ 18 years old. 2. diagnosed as relapsed or refractory non-hodgkin lymphoma . 3. the patient must have measurable diseases. 4. eastern cooperative oncology group (ecog) performance status (ps) score of 0-2. 5. patients must have adequate organ function. 6. expected survival time ≥ 3 months. 7. all toxicities caused by prior anticancer therapy must have recovered to grade ≤ 1 (based on ctcae v5.0) except alopecia and fatigue. 8. female patients of childbearing potential should have a negative blood pregnancy test result within 48 h prior to the first dose of investigational drug. 9. male or female of reproductive age must use contraception from 28 days before the first dose until at least 6 months after the last dose of the study drug. exclusion criteria 1. known active central nervous system (cns) involvement lymphoma. 2. excludes other active malignancies within 3 years before first dose, except locally curable cancers after radical treatment. 3. uncontrolled or severe cardiovascular disorders. 4. presence or history of clinically significant cns diseases. 5. any active infection requiring intravenous infusion for systemic treatment within 14 days prior to the first dose of the study drug. 6. presence or history existence of diseases restricted by the protocol. 7. major surgery within 28 days before first dose. 8. any serious or uncontrolled systemic disease that the investigator believes may increase the risk associated with participating in the study or the administration of the study drug, or may affect the patient's ability to receive the study drug. 9. patients who have received medications or foods with strong inhibitory or inductive effects on cytochrome p450 cyp3a, and proton pump inhibitors within 2 weeks prior to the first dose of investigational drug, or who are planning to receive proton pump inhibitors during the study. 10. patients with a history of intolerance to thalidomide, lenalidomide, or any component contained in the formulation of the investigational drug.
treadmill with biofeedback on gait symmetry after stroke

Conditions: Stroke Syndrome

Summary: this study aims to investigate the immediate, accumulated, and maintainable effects of treadmill with biofeedback on gait symmetry in individuals with chronic stroke.


Eligibility criteria:
inclusion criteria: * single stroke experience * chronic stroke phase: stroke duration ≥ 6 months * independent gait: functional ambulation category (fac) ≥ 3 exclusion criteria: * cognitive problem (mmse \< 24) * visual or audio deficiency that might affect training * severe heart insufficiency or uncontrolled arterial hypertension * orthopedic disorders that affecting their gait

Keywords: gait training biofeedback treadmill gait symmetry
central venous pressure (cvp) assessment by ultrasound and physical examination

Conditions: Central Venous Pressure

Summary: ultrasound may be useful for noninvasively determining the central venous pressure. we intend to compare the clinical examination of the neck veins; ultrasound delineation of the internal jugular vein; and the central venous pressure measured with an intravascular catheter.


Eligibility criteria:
inclusion criteria: * adult medical or surgical icu patients who have preexisting central venous (jugular/subclavian only) catheters. exclusion criteria: * subjects with only a femoral venous catheter. * subjects whose cvp measurement by the indwelling catheter exceeds 20cm of water. * subjects younger than 18 years old. * inability to obtain informed consent from the subject or the subjects authorized representative.

Keywords: cvp us ultrasonography
induction chemotherapy of tpx in nomogram-predicted high risk locoregionally advanced nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: the investigators aim to evaluate the efficiency and toxicities of induction chemotherapy of docetaxel, cisplatin and xeloda in nomogram-predicted high risk locoregionally advanced nasopharyngeal carcinoma.

all eligible patients receive intensity-modulated radiotherapy (imrt) with a total dose of 68 gy or higher in 33 fractions to the primary tumor. nomogram-predicted low risk patients (group a) receive concurrent chemotherapy, while nomogram-predicted high risk patients are randomized to receive concurrent chemotherapy (group b) or induction chemotherapy followed by concurrent chemotherapy (group c). induction chemotherapy consists of docetaxel 65 mg/m², d1, cisplatin 75 mg/m², d1 and xeloda 2000mg/m², d1-14 every 3 weeks for 3 cycles. concurrent chemotherapy consists of cisplatin 100 mg/m², d1 every 3 weeks for 3 cycles.the primary endpoint is failure-free survival (ffs). secondary end points include overall survival (os), locoregional relapse-free survival (lrfs), distant metastasis-free survival (dmfs) and the incidence of grade 3 or higher acute toxicities. all efficacy analyses are conducted in the intention-to-treat population, and the safety population include only patients who receive their randomly assigned treatment.

Eligibility criteria:
inclusion criteria: * newly histologically confirmed non-keratinizing (who 1991) nasopharyngeal carcinoma. * tumor staged as iii-ivb (the 2010 uicc/ajcc staging system). * karnofsky scale (kps) ≥ 70. * adequate marrow: leucocyte count ≥ 4×10e9/l, hemoglobin ≥ 110g/l and platelet count ≥ 100×10e9/l. * normal liver function test: alanine aminotransferase (alt), aspartate aminotransferase (ast) and bilirubin ≤ 1.5×upper limit of normal (uln) concomitant with alkaline phosphatase (alp) ≤ 2.5×uln. * adequate renal function: creatinine clearance ≥ 60 ml/min or creatinine ≤ 1.5×uln. * patients must give written informed consent. exclusion criteria: * prior malignancy, except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer. * pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period). * history of previous radiotherapy (except for non-melanomatous skin cancers outside intended radiotherapy volume). * prior radiotherapy, chemotherapy or surgery (except diagnostic) to primary tumor or nodes. * any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \> 1.5×uln), and emotional disturbance. * deficient in dihydropyrimidine dehydrogenase

Keywords: nasopharyngeal carcinoma induction chemotherapy concurrent chemotherapy docetaxel cisplatin xeloda nomogram
depression attention for women now (the dawn study)

Conditions: Depressive Disorder

Summary: major depressive disorder (mdd) is a common disabling illness that disproportionately affects women, with prevalence rates two times those of men. in addition to suffering, mdd has been shown to have a marked effect on social and vocational functioning, with increased disability, lost productivity, and excess mortality. women with mdd have an increased prevalence of comorbid anxiety disorders and medical conditions. our model of care utilizes a social worker as a depression care manager (dcm) to support both patients and physicians in optimizing care in the ob-gyn clinical setting. this intervention will be compared to usual care for depression.

a large number of women receive their routine care in ob-gyn clinics, including a disproportionate percentage of low-income and minority women. for many of these women, og-gyns are the only provider they see on a regular basis. ob-gyns take care of women across their lifespan, addressing gynecologic, health care maintenance, pregnancy and primary care concerns in their everyday practices. there are multiple aspects of og-gyn care that are uniquely suited for detection and treatment of depression, but there are also significant barriers to such care that must be addressed. in this randomized controlled trial, we are testing this depression care management program for women attending two ob-gyn clinics in the university of washington health care system. our research aims to test the hypothesis that a depression care management intervention, integrated into the ob-gyn clinic setting, will improve treatment outcomes for depression, functional outcomes, and satisfaction with depression care. the results of our research will greatly impact clinical care by satisfying an unmet need for effective depression services for women seen in ob-gyn clinical settings. the study compares a depression care management intervention, delivered by a depression care manager, to usual care for depression in the clinics. the primary aims of the study are to evaluate, compared to usual care, a depression intervention consisting of enhanced education, engagement, and depression care management (with a choice of antidepressant medication monitoring and/or provision of brief psychotherapy).

Eligibility criteria:
inclusion criteria: * phq-9 score ≥10 for major depressive disorder (with 1 cardinal symptom) and/or ≥10 for dysthymia (with 1 cardinal symptom) * mini confirmation of phq-9 diagnoses * access to a telephone * english-speaking exclusion criteria: * high suicide risk (phq-9 response) * ≥2 prior suicide attempts * lifetime history of schizophrenia or bipolar disorder (mini response) * substance abuse/dependence within the previous 3 months (cage-aid) * current severe intimate partner violence * currently seeing a psychiatrist

Keywords: mood disorders depressive disorder women depression
whole body vibration on running biomechanics

Conditions: Knee Osteoarthritis

Summary: whole body vibration (wbv) acutely improves quadriceps strength, and may improve long-term outcomes in individuals with anterior cruciate ligament reconstruction (aclr). however, it is unclear if wbv influences athletic tasks such as running. the purpose of this study is to evaluate the influence of wbv on running biomechanics in individuals with aclr.

individuals with anterior cruciate ligament reconstruction (aclr) have deficits in quadriceps muscles function that influences walking and running biomechanics. in the long term, alterations in walking and running contribute to physical disability and the development of knee osteoarthritis. unfortunately, rehabilitation for the quadriceps muscles is often ineffective, and novel strategies to improve rehabilitation efforts are needed. whole body vibration (wbv) acutely improves quadriceps strength, and may improve long-term outcomes in individuals with aclr. however, it is unclear if wbv influences athletic tasks such as running. specific aim 1: the purpose of this study is to determine the effect of wbv on running biomechanics in individuals with aclr. the investigators hypothesize that wbv will improve running characteristics associated with knee osteoarthritis development.

Eligibility criteria:
inclusion criteria: * 18-35 years * unilateral acl reconstruction * at least 6 months post-reconstruction * recreationally active (at least 20 minutes of physical activity 3 times per week) exclusion criteria: * history of acl graft rupture or revision surgery * neurological disorder * other lower extremity within the 6 months prior to participation
evaluating combined electromagnetic stimulation for enhanced physical and psychological recovery in athletes with doms

Conditions: Recovery, Psychological; Transcranial Magnetic Stimulation

Summary: this randomized controlled trial explores the impact of a combined transcranial and peripheral electromagnetic stimulation over the potential correlation between psychological well-being and recovery outcomes of young athletes experiencing delayed onset muscle soreness.

this randomized controlled trial explores the impact of a combined transcranial and peripheral electromagnetic stimulation (tms and pes) over the potential correlation between psychological well-being and recovery outcomes of young athletes experiencing delayed onset muscle soreness. grounded in the emerging theory of doms as an axonopathy affecting muscle spindles, this study examines whether paired-associative stimulation can show link over physical and psychological recovery processes. forty-eight male athletes, aged 18 to 35 years, regularly engaged in exercise, will be randomly assigned to one of four groups: control (placebo), pes, tms, and combined stimulation (tms + pes). all participants will perform a muscle-damaging exercise protocol to induce doms, followed by the assigned electromagnetic intervention. assessments will include dynamometry, counter movement jump (cmj), visual analog scale for fatigue (vas-f), pain pressure threshold (ppt), sprint performance, and various psychological measures, such as the state-trait anxiety inventory (stai), acceptance and action questionnaire-ii (aaq-ii), and the spanish versions of the big five personality traits, perceived stress scale (pss), and the zung self-rating depression scale. these assessments will be conducted at baseline and at multiple intervals post-exercise (1 hour, 24 hours, 48 hours, and 72 hours).

Eligibility criteria:
inclusion criteria: 1. be male, 2. aged between 18 and 35 years 3. engage in regular exercise at least three times per week for a minimum of one year 4. have no hypersensitivity to the areas designated for peripheral stimulation 5. be free from chronic conditions incompatible with exercise performance 6. have no recent musculoskeletal injuries to the lower limbs within the past six months, 7. be non-smokers 8. possess the cognitive capacity to understand the study's objectives and procedures. exclusion criteria: -

Keywords: transcraneal magnetic stimulation delay onset muscle soreness psychological profile
comparison of cervical cancer screening tests in hiv-infected women in lusaka, zambia

Conditions: Cervical Cancer

Summary: this study will compare the test performance characteristics of visual inspection with acetic acid (via), xpert hpv, and oncoe6 in hiv-infected women, to inform the possible inclusion of these molecular tests in future cervical cancer screening

this is a cross-sectional study taking place at cervical cancer prevention clinics in lusaka, zambia to determine the test performance characteristics (sensitivity, specificity, positive predictive value, and negative predictive value) of (1) visual inspection with acetic acid, (2) xpert hpv, and (3) oncoe6 for the detection of cin2+ among hiv-infected women. all cervical screening tests will be evaluated against a gold standard of histopathology obtained from cervical biopsies.

Eligibility criteria:
inclusion criteria: * women 18 years and older. * women with documented hiv-infection in their medical record or by on-site testing through voluntary counseling and testing. * women willing to undergo pelvic examination and cervical cancer screening. * women willing to provide written, informed consent. exclusion criteria: * pregnancy

Keywords: visual inspection with acetic acid xpert hpv oncoe6 screening